- Forums
- ASX - By Stock
- MSB
- Ann: Long-Term Survival for Acute GvHD Treatment with Remestemcel
Ann: Long-Term Survival for Acute GvHD Treatment with Remestemcel, page-16
-
-
- There are more pages in this discussion • 340 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.49 |
Change
0.025(1.71%) |
Mkt cap ! $1.655B |
Open | High | Low | Value | Volume |
$1.48 | $1.50 | $1.45 | $1.937M | 1.311M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 8057 | $1.49 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.49 | 30097 | 9 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
9 | 6302 | 1.485 |
10 | 20069 | 1.480 |
12 | 44535 | 1.475 |
7 | 63577 | 1.470 |
11 | 140930 | 1.465 |
Price($) | Vol. | No. |
---|---|---|
1.490 | 19019 | 7 |
1.495 | 60171 | 10 |
1.500 | 272166 | 38 |
1.505 | 106357 | 3 |
1.510 | 132904 | 10 |
Last trade - 11.12am 12/11/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online